Clinical Trial

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas

Unknown Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 23, 2024 (before its estimated October 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to explore the safety and feasibility of anti-programmed cell death protein 1(PD-1) immunotherapy, Camrelizumab, combined with cyclin-dependent kinase 4/6 blockade, Dalpiciclib, as a new neoadjuvant treatment regimen for patients with resectable head and neck squamous cell carcinoma(HNSCC).
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06109207
Lead Sponsor West China Hospital
Conditions Head and Neck Squamous Cell Carcinoma
Enrollment 6 participants
Start Date 2023-10-31
Primary Completion 2024-10-31 (estimated)
Study Completion 2025-10-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-23